389 results on '"Chan, H. L.‐Y."'
Search Results
2. Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B
3. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis
4. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
5. Liver fibrosis and fatty liver in Asian HIV-infected patients
6. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B:An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
7. Strategies to manage hepatitis C virus infection disease burden—Volume 4
8. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm: Volume 4
9. Historical epidemiology of hepatitis C virus in select countries—volume 4
10. Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD
11. Machine learning in predicting hepatocellular carcinoma in patients with chronic viral hepatitis in Hong Kong: abridged secondary publication.
12. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma
13. Letter: factors determining liver fibrosis – more to come
14. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B
15. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong
16. Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease – authorsʼ reply
17. Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study
18. Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B
19. Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma – authors’ reply
20. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil
21. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study
22. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
23. Editorial: metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B – authorsʼ reply
24. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B
25. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations
26. Commentary: how long does one need to fast before a Fibroscan examination?
27. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome
28. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments
29. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B
30. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
31. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
32. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma
33. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers
34. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years
35. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir
36. Do we need a histological score to diagnose non-alcoholic steatohepatitis?
37. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance
38. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy
39. Is liver stiffness measurement unreliable in obese patients?
40. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma
41. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
42. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B
43. Potential pitfalls on the validation of liver stiffness measurement by Fibroscan with histological staging in chronic hepatitis B
44. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B
45. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels
46. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B
47. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B
48. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
49. A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China
50. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.